F. García

发表

Viral load in asymptomatic patients with CD4+ lymphocyte counts above 500 × 106/l

Á. Soriano, C. Vidal, T. Pumarola, 1997, AIDS.

Prospective study of antigenemia, plasma viremia and lymphocytic viremia in HIV-infected hemophiliacs

A. Gutierrez, C. R. Pinto, M. Urgellés, 1995, European Journal of Clinical Microbiology and Infectious Diseases.

Safety and eﬃ cacy of the peptide-based therapeutic vaccine for HIV-1, Vacc-4x: a phase 2 randomised, double-blind, placebo-controlled trial

D. Podzamczer, B. Clotet, G. Pantaleo, 2014 .

Clinical Presentation and Outcome of COVID-19 in a Latin American Versus Spanish Population: Matched Case-Control Study

Á. Soriano, J. Mallolas, M. Laguno, 2022, Infectious Diseases and Therapy.

In vitro effects of the CCR5 inhibitor maraviroc on human T cell function.

M. Plana, J. Blanco, J. Gatell, 2013, The Journal of antimicrobial chemotherapy.

Infective endocarditis not related to intravenous drug abuse in HIV-1-infected patients: report of eight cases and review of the literature.

J. Gatell, J. Losa, F. Marco, 2003, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

A randomized study comparing triple versus double antiretroviral therapy or no treatment in HIV-1-infected patients in very early stage disease: the Spanish Earth-1 study.

D. Podzamczer, B. Clotet, J. Romeu, 1999, AIDS.

Effects of highly active antiretroviral therapy on vaccine-induced humoral immunity in HIV-infected adults.

M. Plana, P. Castro, A. Vilella, 2010, HIV medicine.

Lack of evidence of a stable viral load set‐point in early stage asymptomatic patients with chronic HIV‐1 infection

B. Clotet, L. Ruiz, J. Romeu, 1998, AIDS.

Predictors of progression in chronically infected naive patients with plasma viraemia below 5000 copies/ml and CD4 T lymphocytes greater than 500 x 10(6)/I.

M. Plana, Á. Soriano, C. Vidal, 2001, AIDS.

Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy.

M. Plana, C. Vidal, A. Cruceta, 1999, AIDS.

Tocilizumab is associated with reduction of the risk of ICU admission and mortality in patients with SARS-CoV-2 infection

Á. Soriano, M. Laguno, J. Nicolás, 2020, medRxiv.

Cerebrospinal fluid HIV-1 RNA levels in asymptomatic patients with early stage chronic HIV-1 infection: support for the hypothesis of local virus replication.

B. Clotet, L. Ruiz, J. Romeu, 1999, AIDS.

Residual low-level viral replication could explain discrepancies between viral load and CD4+ cell response in human immunodeficiency virus-infected patients receiving antiretroviral therapy.

M. Plana, C. Vidal, A. Cruceta, 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Broadly Cross-Neutralizing Antibodies in HIV-1 Patients with Undetectable Viremia

J. Alcamí, E. Yuste, J. Alcocer-González, 2011, Journal of Virology.

C-reactive protein cut-off for early tocilizumab and dexamethasone prescription in hospitalized patients with COVID-19

Á. Soriano, J. Mallolas, M. Laguno, 2022, Scientific Reports.

The virological and immunological consequences of structured treatment interruptions in chronic HIV-1 infection

G. M. Ortiz, D. Nixon, S. Bonhoeffer, 2001, AIDS.

A nosocomial outbreak of influenza during a period without influenza epidemic activity

T. Pumarola, J. Gatell, C. Codina, 2003, European Respiratory Journal.

Risk of selecting de novo drug-resistance mutations during structured treatment interruptions in patients with chronic HIV infection.

C. Gil, T. Pumarola, J. Miro, 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

HIV therapeutic vaccine enhances non-exhausted CD4+ T cells in a randomised phase 2 trial

R. Tubiana, C. Katlama, B. Autran, 2019, npj Vaccines.

Predictive factors influencing peak viral load drop in response to nucleoside reverse transcriptase inhibitors in antiretroviral-naive HIV-1-infected patients.

B. Clotet, L. Ruiz, C. Vidal, 1998, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

Reappraisal of the aetiology and prognostic factors of severe acute respiratory failure in HIV patients.

J. Miro, J. Gatell, C. Agustí, 2001, The European respiratory journal.

[Disseminated cryptococcosis in patients with AIDS. Prognostic factors of poor outcome].

Á. Soriano, J. Miro, J. Gatell, 1999, Medicina clinica.

Comparison of immunologic restoration and virologic response in plasma, tonsillar tissue, and cerebrospinal fluid in HIV-1-infected patients treated with double versus triple antiretroviral therapy in very early stages: The Spanish EARTH-2 Study. Early Anti-Retroviral Therapy Study.

B. Clotet, J. Romeu, A. Cruceta, 2000, Journal of acquired immune deficiency syndromes.

Comparison of T‐Cell Subsets' Reconstitution After 12 Months of Highly Active Antiretroviral Therapy Initiated During Early Versus Advanced States of HIV Disease

J. Gatell, M. Plana, T. Gallart, 2000, Journal of acquired immune deficiency syndromes.